EPElisabeth P. C. Plompen

Elisabeth P. C. Plompen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elisabeth P. C. Plompen has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Sarwa Darwish Murad

    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, ERN RARE-LIVER Affiliated Center for Rare Vascular Disorders, Rotterdam, The Netherlands

    5 shared publications
  • Harry L.A. Janssen

    Francis Family Chair in Liver Research, Toronto Centre for Liver Disease Professor of Medicine, University of Toronto University Health Network, Toronto General Hospital

    4 shared publications
  • Albert Hofman

    Dept. of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

    3 shared publications
  • Bettina E. Hansen

    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands

    3 shared publications
  • Bruno H. Stricker

    Dept. of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; Dept. of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands

    2 shared publications
  • Daan Willem Loth

    Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands

    2 shared publications

Latest Publications

  • Reply

    by Sarwa Darwish Murad, Edith M. Koehler, Elisabeth P.C. Plompen, Harry L.A. Janssen

  • GI ischemia in patients with portal vein thrombosis: a prospective cohort study

    by Jihan Harki, Elisabeth P.C. Plompen, Désirée van Noord, Jildou Hoekstra, Ernst J. Kuipers, Harry L.A. Janssen, Eric T.T.L. Tjwa


  • Open Access

    ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection

    by Raoel Maan, Adriaan J. van der Meer, Willem Pieter Brouwer, Elisabeth P. C. Plompen, Milan J. Sonneveld, Robert Roomer, Annemiek A. van der Eijk, Zwier M. A. Groothuismink, Bettina E. Hansen, Bart J. Veldt, et al.

    Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with chronic hepatitis C virus (HCV) infection. The aim of the present study was to investigate the association between the functional ITPA variants and hematological side effects during antiviral therapy with pegylated interferon (PegIFN) and RBV. This cohort study included all consecutive Caucasian patients treated for chronic HCV infection with PegIFN and RBV between 2000 and 2009 for whom a serum sample was available for genetic testing. The predicted inosine triphosphate pyrophosphatase (ITPase) activity was based on the genotypes of the SNPs rs1127354 and rs7270101. Decline in hemoglobin (Hb) during antiviral therapy, as well as dose reductions, blood transfusions and use of erythropoietin were assessed. In total, 213 patients were included. The predicted ITPase activity was normal among 152 (71%) patients; 61 (29%) patients had ITPase deficiency. By multivariable linear regression, RBV dose in mg per kilogram (Beta 0.09, 95%CI 0.04–0.13, pITPA gene protected against RBV treatment-induced anemia among Caucasian patients with chronic HCV infection. Patients with normal ITPase activity underwent more dose reductions of RBV and received erythropoietin more frequently.


  • Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population

    by Elisabeth P.C. Plompen, Sarwa Darwish Murad, Bettina E. Hansen, Daan W. Loth, Jeoffrey N.L. Schouten, Pavel Taimr, Albert Hofman, André G. Uitterlinden, Bruno H. Stricker, Harry L.A. Janssen, et al.


  • Top Cited Papers
    Open Access

    Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study

    by Edith M. Koehler, Elisabeth P.C. Plompen, Jeoffrey N.L. Schouten, Bettina E. Hansen, Sarwa Darwish Murad, Pavel Taimr, Frank W.G. Leebeek, Albert Hofman, Bruno H. Stricker, Laurent Castera, et al.

    Given that little is known about the prevalence of, and factors associated with, liver fibrosis in the general population, we aimed to investigate this in a large, well‐characterized cohort by means of transient elastography (TE). This study was part of the Rotterdam Study, a population‐based study among individuals ≥45 years. All participants underwent abdominal ultrasound and TE. Liver stiffness measurement (LSM) ≥8.0 kilopascals (kPa) was used as a cutoff suggesting clinically relevant fibrosis. Of 3,041 participants (age, 66.0 ± 7.6 years) with reliable LSM, 169 (5.6%) participants had LSM ≥8.0 kPa. Age (odds ratio [OR]: 2.40; 95% confidence interval [CI]: 1.72‐3.36; P < 0.001), alanine aminotransferase (ALT; OR, 1.24; 95% CI: 1.12‐1.38; P < 0.001), smoking (OR, 1.77; 95% CI: 1.16‐2.70; P = 0.008), spleen size (OR, 1.23; 95% CI: 1.09‐1.40; P = 0.001), hepatitis B surface antigen, or anti–hepatitis C virus positivity (OR, 5.38; 95% CI: 1.60‐18.0; P = 0.006), and combined presence of diabetes mellitus (DM) and steatosis (OR, 5.20; 95% CI: 3.01‐8.98; P < 0.001 for combined presence) were associated with LSM ≥8.0 kPa in multivariable analyses. The adjusted predicted probability of LSM ≥8.0 kPa increased per age decade, with probabilities ranging from 1.4% (0.9‐3.6) in participants ages 50‐60 years to 9.9% (6.8‐14.5) in participants >80 years. Participants with both DM and steatosis had the highest probabilities of LSM ≥8.0 kPa (overall probability: 17.2% [12.5‐23.4]; this probability did not increase with age [P = 0.8]). Conclusion: In this large population‐based study of older adults, LSM ≥8.0 kPa, suggestive of clinically relevant fibrosis, was present in 5.6% and was strongly associated with steatosis and DM. In the context of an aging population and an increased prevalence of DM and obesity, this study illustrates that liver fibrosis may become a more prominent public health issue in the near future. (Hepatology 2016;63:138–147)


  • Open Access

    Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis

    by E. P. C. Plompen, P. J. M. Valk, I. Chu, S. D. Murad, A. Plessier, F. Turon, J. Trebicka, M. Primignani, J. C. Garcia-Pagan, D. C. Valla, et al.


  • Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study

    by Elisabeth P C Plompen, Bettina E Hansen, Jeoffrey N L Schouten, Sarwa Darwish Murad, Daan W Loth, Willem Pieter Brouwer, Aaron Isaacs, Pavel Taimr, Albert Hofman, Cornelia M van Duijn, et al.

    Dear Editor, Increasing evidence suggests that genetic factors play a role in the multifactorial aetiology of liver fibrosis. In their recent paper, Zhao et al 1 support this by describing the role of the Jnk1 gene in liver fibrogenesis. Previously, the role of other inflammatory-related genes in the development of liver fibrosis has been described in patients with chronic liver diseases. In patients with chronic hepatitis C, Nalpas et al 2 demonstrated a strong association between single nucleotide polymorphisms (SNP) in the interferon gamma receptor 2 ( IFNGR2 ) gene and progression of liver fibrosis. The role of interferon gamma in liver fibrogenesis has been reported before, but the precise mechanism of this effect has not yet been fully elucidated.3 ,4 Currently, it is not known whether the genetic variants in the IFNGR2 gene also influence liver fibrogenesis in individuals without liver disease. Therefore, we aimed to study the association between the IFNGR2 SNPs and liver fibrosis in the general population. For this purpose, we assessed the extent of liver fibrosis non-invasively by measuring liver stiffness (LS) using transient elastography (TE) (Fibroscan, Echosens) in 1059 participants of the Rotterdam study. Genotyping in these, almost exclusively Caucasian (99.6%) participants was performed with the Infinium II HumanHap 550K Genotyping Bead-Chip V.3 (Illumina, San Diego, California, USA). The Rotterdam Study is a large, ongoing, prospective population-based cohort study in subjects aged ≥55 years in …


  • Su1473 Gastrointestinal Ischemia in Patients With Acute and Chronic Portal Vein Thrombosis: A Prospective Study

    by Jihan Harki, Elisabeth P. Plompen, Désirée van Noord, Jildou Hoekstra, Ernst J. Kuipers, Harry Janssen, Eric T. Tjwa

  • Role of anticoagulant therapy in liver disease

    by Elisabeth P. C. Plompen, Jeoffrey N. L. Schouten, Harry L. A. Janssen

    Anticoagulant therapy is a cornerstone in the treatment of different liver diseases. In Budd-Chiari syndrome (BCS), survival rates have increased considerably since the introduction of a treatment strategy in which anticoagulation is the treatment of first choice. In all patients diagnosed with acute portal vein thrombosis (PVT), anticoagulant therapy for at least 3 months is indicated. Anticoagulation should also be considered in patients with chronic PVT and a concurrent prothrombotic risk factor. Current evidence suggests that patients with PVT in cirrhosis will benefit from treatment with anticoagulation as well. In severe chronic liver disease the levels of both pro- and anticoagulant factors are decreased, resetting the coagulant balance in an individual patient and making it more prone to deviate to a hypo- or hypercoagulable state. An increased activity of the coagulation cascade is not solely a feature of chronic liver disease; it influences the development of liver fibrosis as well. Several studies in animals and humans have shown that anticoagulation could prevent or improve fibrogenesis and even disease progression in cirrhosis. Anticoagulation is therefore a promising antifibrotic treatment modality.